VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis pigmentosa patientsVG901, using ViGenerons...
REVeRT, a dual vector approach based on mRNA trans-splicing, enables delivery of genes larger than the usual AAV packaging size in various tissuesPotential to address prevalent inherited diseases...
ViGeneron GmbH, a next-generation gene therapy company, has announced a follow-on collaboration with Daiichi Sankyo Company to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases. Financial terms are not disclosed.
Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates
MUNICH, Germany, April 26, 2022 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) to utilize ViGeneron’s novel engineered recombinant adeno-associated virus vectors (vgAAVs) to address an undisclosed target for the treatment of prevalent eye diseases. Financial terms are not disclosed.
Regeneron receives access to ViGeneron's vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy productViGeneron is...